A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)

Trial Profile

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Lirilumab (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 13 May 2015 According to Innate Pharma media release, data from the trial will be presented at the ASCO (American Society of Clinical Oncology) annual meeting.
    • 17 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top